Sonocatalytic Eradication of Hepatocellular Carcinoma by Tailoring Structural Defects of Black Indium Oxide Sonocatalysts and Leveraging Apoptosis/Ferroptosis‐Hybridized Pathways

Why It Matters

By combining defect‑driven ROS production with enzymatic hypoxia mitigation, the platform dramatically improves sonodynamic therapy efficacy, offering a non‑invasive alternative to conventional liver‑cancer treatments.

Key Takeaways

• Pd‑indium oxide shows enhanced sonocatalytic activity
• Structural defects boost ROS generation under ultrasound
• Catalase-like activity reduces tumor hypoxia
• Hybrid apoptosis‑ferroptosis pathway amplifies cell death
• Platform enables non‑invasive sonodynamic therapy for liver cancer

Pulse Analysis

Sonodynamic therapy (SDT) has emerged as a promising non‑invasive modality for deep‑seated tumors such as hepatocellular carcinoma, yet its clinical impact remains limited by the modest efficiency of existing sonosensitizers. Recent advances in defect engineering demonstrate that introducing vacancies and lattice distortions can dramatically increase acoustic‑induced charge separation, thereby boosting reactive oxygen species (ROS) production. The study leverages black indium oxide, a wide‑bandgap semiconductor, whose abundant structural defects serve as active sites for ultrasound‑driven electron‑hole pairs, laying a robust foundation for next‑generation sonocatalysts.

Integrating palladium nanoparticles onto the indium oxide matrix adds a dual enzymatic function: catalase‑like decomposition of endogenous hydrogen peroxide and peroxidase‑like conversion of H₂O₂ into hydroxyl radicals. This enzymatic mimicry alleviates tumor hypoxia, a major barrier to ROS‑mediated cytotoxicity, while simultaneously amplifying hydroxyl radical flux during ultrasound exposure. The resulting oxidative burst triggers both apoptosis and ferroptosis, a hybrid cell‑death cascade that overwhelms cancer cells’ antioxidant defenses. By coupling defect‑driven charge dynamics with Pd‑mediated chemistry, the platform achieves unprecedented tumor eradication in preclinical models.

The hybrid sonocatalyst points to a broader strategy for precision oncology, where nanomaterials are programmed to remodel the tumor microenvironment and orchestrate multiple death pathways. Its scalable synthesis and reliance on clinically approved ultrasound equipment could accelerate translation into liver‑cancer clinics, potentially reducing reliance on systemic chemotherapy. Moreover, the defect‑engineering paradigm is adaptable to other semiconductor hosts, opening avenues for treating a variety of solid tumors. Investors and biotech firms may view this technology as a high‑value asset in the growing market for non‑invasive cancer therapeutics.